Intensified High-Dose Chemoradiotherapy With Induction Chemotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer-Safety and Toxicity Results Within a Prospective Trial

International Journal of Radiation Oncology Biology Physics

Volumn 76, Issue 3, 2010, Pages 809-815

  Pöttgen, Christoph ^a   Eberhardt, Wilfried E ^a   Gauler, Thomas ^a   Krbek, Thomas ^b   Berkovic, Katharina ^a   Jawad, Jehad Abu ^a   Korfee, Soenke ^a   Teschler, Helmut ^b   Stamatis, Georgios ^b   Stuschke, Martin ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b RUHRLANDKLINIK   (Germany)

Author keywords

Chemoradiotherapy; dose escalation; hyperfractionated accelerated; non small cell lung cancer

Indexed keywords

CHEMORADIOTHERAPY; CIS-PLATIN; CONCURRENT CHEMOTHERAPY; CONFIDENCE INTERVAL; DEFINITIVE RADIOTHERAPY; DOSE ESCALATION; ESOPHAGITIS; HIGH DOSE; INDUCTION CHEMOTHERAPY; LOCOREGIONAL CONTROL RATE; MEAN LUNG DOSE; NON SMALL CELL LUNG CANCER; NONHEMATOLOGIC TOXICITY; OVERALL SURVIVAL RATES; PACLITAXEL; RANDOMIZED TRIAL; TOTAL DOSE; VINORELBINE;

BIOLOGICAL ORGANS; CHEMOTHERAPY; PLATINUM COMPOUNDS; TOXICITY;

FLUORESCENT SCREENS;

ANTIBIOTIC AGENT; CISPLATIN; NAVELBINE; PACLITAXEL; STEROID;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; DYSPNEA; ESOPHAGITIS; ESOPHAGUS DISEASE; FEMALE; FEVER; HUMAN; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MALE; MEDIASTINOSCOPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; OVERALL SURVIVAL; PATIENT SAFETY; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SKIN FIBROSIS; SURVIVAL RATE; THROMBOCYTOPENIA;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; ESOPHAGITIS; FEMALE; HUMANS; LEUKOPENIA; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; PNEUMONIA; PROSPECTIVE STUDIES; REMISSION INDUCTION; SURVIVAL ANALYSIS; VINBLASTINE;

EID: 76049128982     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.02.022     Document Type: Article

References (24)

1. Mountain C.F. Revisions in the International System for Staging Lung Cancer. Chest 111 (1997) 1711-1717
2. De Camp M., Ashiku S., and Thurer R. The role of surgery in N2 non-small cell lung cancer. Clin Cancer Res 11 13 Suppl. (2005) 5033s-5037s
3. Auperin A., Le Pechoux C., Pignon J.P., et al. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): A meta-analysis of individual data from 1764 patients. Ann Oncol 17 (2006) 473-483
4. Eberhardt W., Pöttgen C., and Stuschke M. Chemoradiation paradigm for the treatment of lung cancer. Nature Clin Pract Oncol 3 (2006) 188-199
5. Giraud P., De Rycke Y., Minet P., et al. Estimation of the probability of mediastinal involvement: a statistical definition of the clinical target volume for 3-dimensional conformal radiotherapy in non-small-cell lung cancer?. Cancer Radiother 5 (2001) 725-736
6. Akerley W., Herndon J.E., Lyss A.P., et al. Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: A limited-access study-CALGB 9534. Clin Lung Cancer 7 (2005) 47-53
7. Vokes E.E., Herndon J.E., Kelley M.J., et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 25 (2007) 1698-1704
8. SAS Institute. SAS/STAT user's guide, version 6. 4th ed., vol. 1/2 (1989), SAS Institute Inc., Cary, NC
9. Kaplan E.L., and Meier P. Non parametric estimation from incomplete information. J Am Stat Assoc 53 (1958) 457-481
10. Gauler T., Hepp R., Bildat S., et al. Induction chemotherapy (CTx) and definitive concurrent chemoradiation (RTx/CTx) in locally advanced non-small cell lung cancer (NSCLC) stage III: Further treatment optimization with novel agents. [Abstract]. Lung Cancer 37 Suppl. 1 (2002) S29
11. Pöttgen C., Eberhardt W., Bildat S., et al. Induction chemotherapy followed by concurrent chemotherapy and definitive high-dose radiotherapy for patients with locally advanced non-small-cell lung cancer (stages IIIa/IIIb): A pilot phase I/II trial. Ann Oncol 13 (2002) 403-411
12. Rosenzweig K.E., Sura S., Jackson A., et al. Involved-field radiation therapy for inoperable non-small-cell lung cancer. J Clin Oncol 25 (2007) 5557-5561
13. Werner-Wasik M., Swann R.S., Bradley J., et al. Increasing tumor volume is predictive of poor overall and progression-free survival: Secondary analysis of the Radiation Therapy Oncology Group 93-11 phase I-II radiation dose-escalation study in patients with inoperable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 70 (2008) 385-390
14. Schild S.E., McGinnis W.L., Graham D., et al. Results of a phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 65 (2006) 1106-1111
15. Socinski M.A., Blackstock A.W., Bogart J.A., et al. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALBG 30105. J Clin Oncol 26 (2008) 2457-2463
16. Vokes E.E., Herndon J.E., Crawford J., et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: Cancer and Leukemia Group B study 9431. J Clin Oncol 20 (2002) 4191-4198
17. Bradley J.D., Graham M., Suzanne S., et al. Phase I results of RTOG L-0117: A phase I/II dose intensification study using 3dCRT and concurrent chemotherapy for patients with inoperable NSCLC. [Abstract]. J Clin Oncol 23 Suppl. 16S (2005) 636s
18. Yuan S., Sun X., Li M., et al. A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer. Am J Clin Oncol 30 (2007) 239-244
19. Stamatis G., Eberhardt W., Stüben G., et al. Preoperative chemoradiotherapy and surgery for selected non-small cell lung cancer IIIB subgroups: Long-term results. Ann Thorac Surg 68 (1999) 1144-1149
20. Stamatis G., Djuric D., Eberhardt W., et al. Postoperative morbidity and mortality after induction chemoradiotherapy for locally advanced lung cancer: An analysis of 350 operated patients. Eur J Cardiothorac Surg 22 (2002) 292-297
21. Saunders M., Dische S., Barrett A., et al. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in NSCLC: A randomized multicenter trial. Lancet 350 (1997) 161-165
22. Belani C.P., Wang W., Johnson D.H., et al. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): Induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer. J Clin Oncol 23 (2005) 3760-3767
23. Albain K.S., Swann R.S., Rusch V.R., et al. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): Outcomes update of North American Intergroup 0139 (RTOG 9309). [Abstract]. J Clin Oncol 23 Suppl. (2005) 7014
24. Albain K.S., Rusch V.W., Crowley J.J., et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: Mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 13 (1995) 1880-1892